Cafepharma Today

June 2 2025 - Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Sanofi expands rare immunology portfolio with Blueprint buyout
Moderna's next-gen COVID shot gets FDA backing with some limitations
BioNTech flips its cancer bispecific to BMS for a big profit
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Pfizer's approach may turn hostile after AZ rejects second offer
Fierce Pharma
Friday, May 2, 2014 - 11:16am
tags:
Pfizer, M&A, AstraZeneca
Zimmer launches $4.35B pro rata package for Biomet buy
Reuters
Friday, May 2, 2014 - 11:12am
tags:
Zimmer, M&A, Biomet
Is Big Pharma Ready to Jump Into the Marijuana Market?
Wall St Cheat Sheet
Friday, May 2, 2014 - 10:52am
tags:
Medical Marijuana
The Real Reason Behind Pfizer's Bid For AstraZeneca
Motley Fool
Friday, May 2, 2014 - 10:49am
tags:
Pfizer, M&A, AstraZeneca
Avanir Pharmaceuticals: Riding On A Non-Fundamental Catalyst
Seeking Alpha
Friday, May 2, 2014 - 10:48am
tags:
Avanir, Neudexta
Genentech granted FDA orphan status for gastric cancer treatment
Yahoo/Fly on the Wall
Friday, May 2, 2014 - 9:53am
tags:
Genentech, FDA, gastric cancer, cancer of the gastro-esophageal junction, orphan drugs, Ipatasertib
3 Numbers That Don’t Lie About The AstraZeneca plc Takeover Offer
Motley Fool
Friday, May 2, 2014 - 8:42am
tags:
AstraZeneca, Pfizer, M&A
Merck and Endocyte's ovarian cancer drug fails in trial
Yahoo/Reuters
Friday, May 2, 2014 - 8:40am
tags:
Merck, Endocyte, ovarian cancer, vintafolide
Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth
Motley Fool
Friday, May 2, 2014 - 8:39am
tags:
earnings, Seattle Genetics
BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales
Motley Fool
Friday, May 2, 2014 - 8:38am
tags:
Biomarin, earnings
Despite Esbriet Sales Nearly Tripling, InterMune's Loss Widens by 7%
Motley Fool
Friday, May 2, 2014 - 8:37am
tags:
earnings, InterMune
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Motley Fool
Friday, May 2, 2014 - 8:37am
tags:
earnings, Exelixis
Acorda Therapeutics says FDA rejects epilepsy drug
Yahoo/Reuters
Friday, May 2, 2014 - 8:35am
tags:
FDA, epilepsy, Acorda Therapeutics, Plumiaz
MedTech's Partial Tax Repeal: Is It Enough?
Yahoo/Zacks.com
Friday, May 2, 2014 - 8:33am
tags:
devices, device tax
Pfizer new $106.5B offer ‘inadequate’: AstraZeneca
CNBC
Friday, May 2, 2014 - 8:30am
tags:
Pfizer, AstraZeneca, M&A
Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S
Yahoo/Reuters
Friday, May 2, 2014 - 8:28am
tags:
Ranbaxy, recalls
Vertex's Sales Plunge 64% as It Refocuses Its Pipeline on Cystic Fibrosis Therapies
Motley Fool
Thursday, May 1, 2014 - 10:15pm
tags:
cystic fibrosis, Vertex Pharmaceuticals, hepatitis C, earnings
Bayer nears deal to buy Merck consumer unit -sources
Yahoo/Reuters
Thursday, May 1, 2014 - 5:16pm
tags:
Bayer, consumer health, M&A
Pfizer prepares sweeter bid for AstraZeneca: report
Yahoo/Reuters
Thursday, May 1, 2014 - 2:58pm
tags:
Pfizer, AstraZeneca, M&A
Pharma preps for Sunshine inquiries
Medical Marketing & Media
Thursday, May 1, 2014 - 10:09am
tags:
Physician Payment Sunshine Act, physician payments

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.